Adaptive Biotechnologies (ADPT) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Twist Bioscience (TWST) has outperformed Adaptive Biotechnologies (ADPT) over the past year, gaining 261.8% versus a gain of 50.1%. Over five years, TWST leads with a +8.8% price change compared with -0.7% for ADPT. Twist Bioscience is the larger company by market cap ($7.04 billion vs $4.52 billion), about 1.6 times the size, while Adaptive Biotechnologies is growing revenue faster (+54.8% vs +22.0%).
Adaptive Biotechnologies converts more of its revenue into profit, with a net margin of -21.5% versus -28.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | TWST |
|---|---|---|
| Share price | $27.93 | $103.32 |
| Market cap | $4.52B | $7.04B |
| 1-day change | -0.43% | -7.44% |
| YTD return | +71.98% | +225.73% |
| 1-year return | +50.08% | +261.76% |
| 5-year return | -0.68% | +8.77% |
| EPS (TTM) | $-0.45 | $-2.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $459.43M |
| Revenue growth (YoY) | +54.77% | +22.00% |
| Net income (latest FY) | $-59.50M | $-130.20M |
| Gross margin | 74.24% | 52.41% |
| Operating margin | -20.62% | -30.35% |
| Net margin | -21.48% | -28.34% |
| 52-week high | $32.21 | $219.71 |
| 52-week low | $12.00 | $28.27 |
| Distance from 52-week high | -13.29% | -52.97% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +21.23% | +24.68% |
| Average volume | 2.20M | 2.49M |
| Shares outstanding | 161.88M | 68.18M |
| Employees | 624 | 1,080 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed ADPT by 211.7 percentage points over the past year.
- Adaptive Biotechnologies is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -28.3 cents for Twist Bioscience.
- Adaptive Biotechnologies grew revenue faster in its latest fiscal year (+54.77% vs +22.00%).
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees
ADPT vs TWST FAQ
Which is bigger, Adaptive Biotechnologies or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $7.04B compared with $4.52B for Adaptive Biotechnologies (ADPT).
Which stock has performed better over the past year, ADPT or TWST?
TWST returned +261.76% over the past 12 months, compared with +50.08% for ADPT (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.